Search - tctmd.com

Displaying 521 - 540 of 1051

Sort: Relevancy | Date

Podcast TCTMD Talking Points

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

September 05, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Conference News ESC 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

Michael O'Riordan

August 25, 2018

News Daily News

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

Michael O'Riordan

August 14, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

L.A. McKeown

August 09, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Discharge Against Medical Advice After PCI Rare but Deadly

Michael O'Riordan

July 17, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Todd Neale

June 25, 2018

Podcast Heart Sounds

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

Advertisement

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

TCTMD’s Top 10 Most Popular Stories for August 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Discharge Against Medical Advice After PCI Rare but Deadly

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

Top Stories in Cardiology: May 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content